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The development of postattenuation neurologic signs (PANS) is a poorly
understood and potentially devastating complication after surgical attenuation
of congenital portosystemic shunts in dogs. Postattenuation neurologic signs
include seizures but also more subtle neurologic signs such as depression,
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behavioral changes, tremors, and twitching. They most commonly occur
within 7 days postoperatively and are typically unrelated to hyperammonemia,
hypoglycemia, or electrolyte disturbances. This narrative review summarizes
the findings of 50 publications from 1988-2020 that report occurrence of PANS.
While most published reports included only dogs affected by postattenuation
seizures (PAS), others included dogs with any form of PANS. Overall, PANS
(including PAS) affected 1.6%-27.3% of dogs, whereas incidence of PAS ranged
from 0%-18.2%. The etiology of PANS remains unknown; however, several the-
ories have been proposed. Risk factors include preoperative hepatic encepha-
lopathy, increasing age, and possibly certain breeds and extrahepatic shunt
morphology. There is increasing evidence that prophylactic antiepileptic drugs
do not prevent PANS. Treatment is centered around controlling neurologic
signs with antiepileptic drugs and providing supportive intensive care. The
30-day survival rate in studies that included a minimum of four dogs affected
by PANS was 0%-100% (median, 50.0%) and 0%-75.0% (median, 37.5%) for
those with PAS. Mortality associated with PANS was typically related to occur-
rence of generalized seizure activity. Prognostic factors positively associated
with short-term survival included having a history of preoperative seizures and
development of focal seizures only. If affected dogs survived to discharge, sur-
vival for several years was possible, and the majority of neurologic signs
manifested as part of the phenomenon of PANS appeared to resolve.
1 | INTRODUCTION
In 1988, Mathews and Gofton1 reported fatal postattenuation
seizures (PAS) in 3 dogs without preoperative seizures after
surgical attenuation of a congenital extrahepatic por-
tosystemic shunt (cEHPSS). Since then, occurrence of PAS or
other postattenuation neurologic signs (PANS) has been
mentioned or described in detail in 49 further reports.2–50
Several terms have been used to describe this complication,
including postligation seizure syndrome,11,27 postligation
neurologic dysfunction,11,13,17,20,21,34 postligation neurologic
syndrome,18,25 postligation seizures,11,16,39,42 postattenuation
neurologic signs,41,50 and postattenuation seizures.46,47 While
several investigators have described the occurrence of
seizures,1,2,4,6–9,12,14,16,17,23–27,29–35,37–40,42,45–49 others have rec-
ognized that this phenomenon can manifest as more subtle
neurologic signs such as depression, ataxia, behavioral
change, tremors and twitching.5,10,11,13,15,18,20,22,28,41,43,50 Pos-
tattenuation neurologic signs has been defined as manifesta-
tion of any postoperative neurologic signs (including
seizures) between surgery and discharge41 (most commonly
within 7 days postoperatively) and typically unrelated to
hyperammonemia, hypoglycemia, or electrolyte distur-
bances.12,13,16,38,39,41,46,47 This complication is considered
distinct to hepatic encephalopathy (HE) for several reasons,
including its occurrence even after complete shunt liga-
tion1,13,15,41,43,46 and in dogs without preoperative neurologic
signs or seizures, its frequently refractory nature in compari-
son to preoperative neurologic signs,2,13,17,32,38,47 and its
occurrence even in the face of normal or near normal ammo-
nia concentrations.1,4,12,13,16,32,38,41,46
The objective of this narrative review is to summarize
the available literature pertaining to incidence, etiology,
and risk factors for PANS in dogs, as well as the use of
prophylactic antiepileptic drug(s) (AEDs), treatment, and
prognosis for survival and outcome.
2 | SEARCH STRATEGY
An electronic literature search was performed in January
2021 using the PubMed database (www.ncbi.nlm.nih.
gov/PubMed) with the aim of identifying all peer-
reviewed articles without date restriction that reported
occurrence of PANS in dogs. Search strategy details are
presented in Appendix S1 in File S1. Exclusion criteria
included articles in a non-English language, experimental
or in vitro studies, reviews, editorials, letters to the editor,
and studies that did not describe occurrence of PANS.
Potential additional references were searched from refer-
ence lists of final PubMed selected articles. Article selection
and data extraction were performed by the primary author.
The electronic search identified 962 citations, of which
706 were excluded based on their title and abstract. The
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remaining 256 manuscripts were read in full, with 48 articles
meeting the inclusion criteria.2,4–50 Reference lists within these
48 articles were hand searched for potential additional refer-
ences, which yielded a further two articles meeting the inclu-
sion criteria.1,3 Reference lists within these two articles were
again hand searched and no further articles were identified.
3 | INCIDENCE OF
POSTATTENUATION NEUROLOGIC
SIGNS
Most published reports include only dogs affected by
PAS,1,2,4,6–9,12,16,17,23–27,29–35,37–40,42,45–49 but others include dogs
that manifest any form of PANS.5,10,11,13–15,18–22,28,36,41,43,44,50
Within the latter reports,5,10,11,13–15,18–22,28,36,41,43,44,50 PANS
affected 2.6%-27.3% dogs. Overall, PANS (including PAS)
affected 1.6%-27.3% of dogs (Appendix S2 in
File S1).1,2,4–11,13–15,18–29,31–37,39–46,48–50 The true incidence
of PANS may be underreported as subtle neurologic
signs may go unrecognized.36,41 Postattenuation
seizures are described predominantly after attenuation
of cEHPSS, with a reported incidence of 0%-
18.2%.1,2,4,7,10,11,13,15,18,19,23,25,27–29,31,32,34,37,39,41,44–46,48–50 Incidence
of PAS after congenital intrahepatic portosystemic shunt
(cIHPSS) attenuation ranges from 0%-14.3% (Appendix S2 in
File S1).7,9,19,22,26,40,41,43
4 | ETIOLOGY OF
POSTATTENUATION NEUROLOGIC
SIGNS
Etiology of PANS remains unknown; however, several
theories have been proposed.
4.1 | Central nervous system (CNS)
disease/derangement
4.1.1 | Altered central nervous system
metabolism
Based on a single study,51 one PANS theory is that a
decrease in systemic concentrations of endogenous ben-
zodiazepines derived from the gastrointestinal tract
occurs after shunt attenuation. Mean concentrations of
endogenous benzodiazepines in portal and arterial blood
of 15 dogs with congenital portosystemic shunts (cPSS)
were significantly (P < .05) higher than those of eight
healthy controls.51 Investigators proposed that if shunting
caused stimulation of brain benzodiazepine receptors, a
decline in systemic concentrations after shunt attenuation
could result in seizures.51 A decrease in cerebrospinal fluid
(CSF) concentrations of endogenous benzodiazepines and
changes in concentrations of neurotransmitters have also
been theorized to precipitate seizures.2 This theory relating
to a decline in systemic or CSF endogenous benzodiazepine
concentrations fails to explain the occurrence of PANS after
partial ligation1,2,4,9,13,15,16,18,19,43,46 and delayed attenuation
techniques.10,13,17–19,21,23,25–28,30,32,34,37,39,40,44–50 Administra-
tion of benzodiazepines has also proven unreliable in the
management of PANS.2,13,17,18,32
It is recognized that dogs with cPSS have significantly
(P < .0001) increased whole blood manganese concentra-
tions compared with healthy controls.52 In rats, exposure
of astrocytes to manganese is associated with
upregulation of “peripheral type” benzodiazepine recep-
tors;53 however, an association in dogs has not been
investigated. Torisu and colleagues54 identified
hyperintensity of the lentiform nuclei on T1-weighted
images in dogs with cPSS, which decreased after surgical
attenuation. In a case report by the same investigators,30
lentiform nuclei were confirmed to have significantly
higher (> 4 times) manganese concentrations (as well as
approximately twice the concentration of iron and cop-
per) in a dog with PAS that was euthanized compared
with a control group.
Postattenuation neurologic signs do not appear to be
a manifestation of postoperative hyperammonemic-HE
and seem distinct from neurologic signs observed preopera-
tively related to HE.16 They are reported predominantly in
the presence of normal/near normal or significantly
decreased (compared with preoperatively) ammonia
concentrations,1,4,12,13,16,32,38,41,46 with only a few reported
cases with concurrent hyperammonemia.2,4,30,41,46 In a ret-
rospective study involving 253 dogs (28 of which developed
PANS),41 no significant difference in preoperative or postop-
erative ammonia concentrations was identified among dogs
that did or did not experience PANS or PAS. In another ret-
rospective study involving 75 dogs affected by PAS,46
ammonia concentrations around the time of PAS occur-
rence were <70.0 μmol/L in 76.7% of dogs for which values
were available. In a further retrospective study involving
93 dogs with PAS (many of which were included in the pre-
vious study46),47 dogs with a history of preoperative seizures
had a median ammonia concentration of 46.0 (range,
13.0-104.0) μmol/L (<70 μmol/L considered normal)41,47 at
the time of PAS. Some dogs with HE can have normal
ammonia concentrations and the possibility of an unknown
biochemical factor resulting in a nonhyperammonemic HE
has been proposed as an explanation for PANS.4,55 How-
ever, absence of preoperative HE in some dogs and the
refractory nature of PANS in comparison to preoperative
HE suggest an alternative etiology than postoperative con-
tinuation of HE.4,17 Investigators in an older retrospective
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case series2 considered the presence of HE-induced brain
lesions as a possible cause for PAS in four dogs; however,
histologic signs supporting this were not identified on nec-
ropsy of two brain specimens.2
Occurrence of one or more postoperative metabolic
events in the face of shunting-induced CNS damage has
been theorized to result in PAS.2 It has also been
suggested the CNS of dogs with cPSS becomes adapted to
a state of altered metabolism and that a change in this
altered metabolic state postattenuation precipitates
PAS.4,13 The presence of HE immediately preoperatively
has been identified as a risk factor for PANS and PAS,41
with investigators proposing that a larger relative change
in CNS environment postattenuation could be responsi-
ble for PANS.41
4.1.2 | Concurrent brain disease
Concurrent brain disease, including idiopathic epilepsy,
congenital, inflammatory and noninflammatory brain dis-
ease, has been suggested as a possible cause of PANS.2,13,44
A congenital etiology, cerebral cortical disease, and idio-
pathic epilepsy were considered unlikely by investigators
in a small retrospective case series2 because of the positive
preoperative response to treatment of HE in three affected
dogs and absence of preoperative neurologic signs in
another dog. In another retrospective case series,4 only
2 of 5 dogs with generalized PAS demonstrated preopera-
tive neurologic signs, suggesting that pre-existing brain
disease was not responsible for postoperative generalized
seizures. A limitation of these case series2,4 is that they
include a total of only 9 dogs. Evidence of inflammatory or
congenital (eg, hydrocephalus) brain disease has not been
identified on necropsy in affected dogs.2,4,20,23,39,44 Cere-
brospinal fluid obtained from three dogs with cPSS identi-
fied mild inflammation in two2,4 (suspected due to
prolonged seizure activity in one dog),2 and was normal in
the third dog.1 In a retrospective study,44 no evidence of
necrotizing meningoencephalitis was identified on nec-
ropsy in any pug that developed PANS and subsequently
died. Reye's syndrome, a rare and potentially fatal ill-
ness in people involving acute noninflammatory
encephalopathy with fatty liver failure, has also been
suggested as a possible cause of PAS but it was consid-
ered unlikely on the basis of decreased ammonia con-
centrations postoperatively and lack of elevated liver
enzymes.2 As far as we are aware, Reye's syndrome has
not been reported in dogs. Using single photon emis-
sion computed tomography (SPECT), one study dem-
onstrated areas of regional hypoperfusion and
hyperperfusion within the brain of 8 dogs with cPSS
and HE compared with 8 normal dogs.56
4.1.3 | Acquired brain disease
Hypertensive encephalopathy has been considered a pos-
sible cause of PAS.2 However, blood pressure during sei-
zure activity has been reported in only four dogs and was
within normal limits in all cases.2,32 Severe intraoperative
hypotension has also been suggested as a cause of PAS
because of secondary brain ischemia and subsequent
neuronal necrosis.39 However, no difference in incidence
of PAS among dogs that did (8.4%) or did not (7.4%) expe-
rience intraoperative hypotension was identified in one
retrospective study.39 Finally, hypoxemia/brain hypoxia
has been proposed as a possible cause of PAS;2,4,32,44
however, there is no strong evidence to support this. In
two small retrospective case series,2,4 lesions consistent
with hypoxia/anoxia identified in brain specimens of four
nonsurvivors were suspected to be due to seizure activity
rather than a cause.
4.2 | Perioperative hypoglycemia
Perioperative hypoglycemia is a recognized complication
of cEHPSS attenuation in small dogs.57 Hypoglycemia is
sporadically reported in dogs with PAS1,2,4,46,47 but there
are many reported cases of PANS and PAS that occurred
with normoglycemia.1,4,10–13,16,17,32,38,39,44,46 In a retro-
spective study involving 75 dogs with PAS,46 glucose con-
centrations at the time of seizure occurrence were
≥3.3 mmol/L in 91.9% dogs for which values were avail-
able. There are at least four reports of affected dogs
receiving dextrose-containing fluids or eating voluntarily
when PANS first commenced.1,4,12,13 Postattenuation
neurologic signs can also progress despite treatment to
correct hypoglycemia.2,4 Hypoglycemia-induced brain
lesions may be an explanation but this concept has not
been investigated.2
4.3 | Perioperative electrolyte
disturbances
Variable degrees of derangement in electrolyte concentra-
tions have been identified in a limited number of dogs at
the time of PAS.2,4,16,25,47 Low to low-normal total cal-
cium concentrations have been reported in at least seven
dogs affected by PAS; however, ionized hypocalcemia
was confirmed in only a single dog.2,13,16 Intravenous cal-
cium supplementation in at least two of these dogs did
not arrest seizures.2,13 Hypokalemia has also been identi-
fied in dogs affected by PAS and correction similarly did
not always abolish seizures.2,16,46,47 There are many more
reported cases of PAS occurring in the face of normal
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electrolyte concentrations and the potential contribution
of electrolyte derangement to occurrence of PANS
remains unclear.12,32,38,46,47
4.4 | Postoperative portal hypertension
A clear association between PANS and portal hyperten-
sion has not been demonstrated and there are several
reports of PANS despite intraoperative measurement of
portal pressures and adherence to recommended guide-
lines for attenuation.1,2,4,10–12,17,41 There are occasional
reports of portal pressures measured at the time of
PAS.2,4 In one affected dog, portal pressures measured
via a catheter that had been left in situ in a jejunal vein
were consistently within normal limits.4 No evidence of
portal hypertension was identified, either grossly or fol-
lowing measurement of portal pressures in two affected
dogs that underwent repeat celiotomy during PAS.2,4
There is one report11 of PANS persisting after ligature
removal for treatment of concurrent postoperative portal
hypertension and another report10 of PANS developing
after ligature removal. No gross evidence of portal hyper-
tension was identified at necropsy in two dogs.1
4.5 | Infectious disease
An infectious cause for PANS has not been identified. In
a small case series,2 serologic testing for canine distemper
virus in two dogs yielded negative results and CSF bacterial
culture from one dog failed to identify a causative organism.
5 | RISK FACTORS FOR
POSTATTENUATION NEUROLOGIC
SIGNS
Potential risk factors for PANS include:
5.1 | Presence of immediately
preoperative hepatic encephalopathy
Neurologic signs consistent with HE are frequently diag-
nosed in dogs with cPSS but few studies report the preva-
lence of HE immediately preoperatively.41 In a retrospective
study involving 253 dogs,41 the presence of HE immediately
preoperatively was a risk factor for PANS (odds ratio
[OR] 2.704, CI 1.057-6.922) and PAS (OR 3.538, CI
1.013-12.363). The presence of more severe CNS changes58,59
(eg, astrocyte swelling caused by neurotoxic substances such
as ammonia), a less stable neurologic state, and a greater
relative change in CNS biochemical environment after
shunt attenuation were considered to be implicated.41 This
highlights that preoperative medical stabilization of HE
should be a priority where possible.
5.2 | Increasing age
Increasing age has been identified in a recent study as a risk
factor for PANS (OR 1.476, CI 1.223-1.780) and PAS
(OR 1.364, CI 1.082-1.720),41 corroborating observations of
several previous investigators.2,4,13,23,41,44,46,47 It has been
suggested that the brain of older dogs is exposed to the
abnormal metabolic consequences of shunting for longer or
becomes adapted to a state of abnormal metabolism, with
shunt attenuation in such dogs precipitating PANS.4,41 Pos-
tattenuation neurological signs have also been reported in
dogs <12 months old1,2,4,16,17,21,23,25,32,41,43,47 and some stud-
ies report no significant difference in age of dogs that did or
did not develop PANS.13,21,44
5.3 | Extrahepatic portosystemic shunt
morphology
Postattenuation neurological signs (including PAS)
have been reported predominantly after correction of
cEHPSS,1,2,4,10–13,15,18,19,21,23,25,27–29,31,32,34,37–39,41,44–50 with
fewer reports after cIHPSS attenuation.5,7,9,16,17,21,22,26,36,40,41,43
In one retrospective study involving 89 dogs,13 those
with cEHPSS (12.4%) were more likely (P = .03) to
develop PANS than dogs with cIHPSS (0.0%). However,
this is not supported by two larger retrospective studies
involving 106 and 253 dogs, respectively.21,41 The inci-
dence of PAS after cEHPSS attenuation is 0%-
18.2%1,2,4,7,10,11,13,15,18,19,23,25,27–29,31,32,34,37,39,41,44–46,48–50 and
0%-14.3%7,9,19,22,26,40,41,43 after cIHPSS attenuation (Appendix
S2 in File S1). PANS are reported after attenuation of
portocaval, portophrenic, and portoazygos shunt sub-
morphologies.10,13,46,47 One retrospective study identified a
trend toward dogs with portoazygos shunts being at greater
risk of PANS than dogs with portocaval shunts.13 Dogs with
portoazygos shunts tend to be older at diagnosis than dogs
with portocaval shunts and it is possible that their older age
is responsible for increased risk of PANS in such dogs rather
than the shunt submorphology.13
5.4 | Certain breads
Certain breeds have been suggested to be at increased
risk of PANS, including Jack Russell terriers,21 pugs10,13,44
and Maltese .1,13 However, these observations are derived from
small study populations.
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6 | FACTORS THAT HAVE NOT
BEEN FOUND TO BE ASSOCIATED
WITH INCREASED RISK OF
POSTATTENUATION NEUROLOGIC
SIGNS
6.1 | Method and degree of acute
intraoperative shunt attenuation
Postattenuation neurologic signs are reported after
complete and partial suture ligation;1,2,4,6,7,9,11–16,18,24,31,38,41,46,47
delayed attenuation techniques, including thin film banding
(TFB);10,13,17,21,25,27,30,39,40,44–48,50 ameroid constrictor (AC)
placement,16,18,23,26,28,32,34,39,44,46–48,50 and endovascular
techniques.36,40 The incidence of PAS after suture ligation,
TFB and AC placement is 0%-18.2%,1,2,4,6–9,11,13–15,18–
20,22,24,26,28,31,35,42,43 1.8%-18.2%,10,13,25,27,37,40,45,48,50 and 0%-
13.0%,15,18,19,23,26,28,34,45,48,50 respectively (Appendix S2 in
File S1). The incidence of PAS after coil embolization in
dogs with cIHPSS was 3.7% in one study.40 In another
study,36 PANS occurred in eight (8.4%) of 95 dogs undergo-
ing coil embolization of cIHPSS. A number of investigators
have compared the incidence of PANS directly between
individual methods of shunt attenuation.13,40,48 Two studies
found no significant difference in incidence of PAS among
dogs with cEHPSS treated with TFB or AC.48,50 No signifi-
cant difference in incidence of PANS was identified among
dogs with cEHPSS that underwent partial attenuation with
silk (14.3%) or TFB (11.4%) in another study.13 Case and
colleagues40 reported PAS in 9.7% dogs with cIHPSS
after TFB and 3.7% after coil embolization; however, the inves-
tigators did not state if the difference was statistically
significant.
No association has been identified between degree of
acute intraoperative shunt attenuation and occurrence of
PANS. In one retrospective study,13 8.3% of dogs undergo-
ing complete ligation with silk experienced PANS, in
comparison to 13.0% of dogs that underwent partial attenua-
tion with silk or TFB (P = .6). In a large-scale retrospective
study,41 the degree of shunt attenuation (complete ligation
vs. TFB or partial ligation) was not associated with PANS or
PAS. Degree of intraoperative shunt occlusion with TFB
(<3 mm versus no occlusion) was also not associated with
occurrence of PANS in another study.25
6.2 | Preoperative neurologic signs or
seizures
As discussed previously, the presence of immediately
preoperative hepatic encephalopathy has been identified
as a risk factor for PANS and PAS.41 However, a clear
association between presence of preoperative neurologic
signs or seizures overall (not just in the immediate pre-
operative period) and occurrence of PANS or PAS has
not been identified.41 In three large retrospective
studies,13,41,48 no difference in the incidence of PANS or
PAS was identified among dogs that did or did not have
preoperative neurologic signs/HE. However, investiga-
tors in two of these studies do not report specific timing
of neurologic signs prior to surgery.13,48 Absence of pre-
operative neurologic signs/HE (prior to medical man-
agement or immediately preoperatively) does not
exclude the possibility of PANS.39,41,47 In a study that
included 93 dogs affected by PAS,47 approximately 25%
of affected dogs did not have preoperative neurologic
signs and only 17.2% had preoperative seizures. In
another retrospective study,23 only 1 of 7 dogs with PAS
had preoperative seizures, while in 3 small case
series4,16,32 and a case report,17 no dog with generalized
PAS had a history of preoperative seizures.
6.3 | Surgical or anesthesia time
In a retrospective study that included 124 dogs,39 neither
surgical nor anesthetic time was significantly different
among dogs that did or did not experience PAS.
6.4 | Postoperative changes in natremia/
serum osmolality
Investigators in a retrospective study proposed that PANS
may be related to postoperative changes in natremia/
osmolality.41 In that study,41 serum osmolality was signif-
icantly higher at two postoperative time points (median
of 8 [P = .016] and 24 h [P = .020] postoperatively) in
dogs affected by PANS and at all 3 postoperative time
points (median of 1 [P = .001], 8 [P = .002], and 24 h
[P = .006] postoperatively) in dogs affected by PAS com-
pared with unaffected dogs. However, osmolality did not
remain statistically significant in the multivariable analy-
sis.41 There are no further studies investigating serum
osmolality in dogs with PANS.
7 | USE OF PROPHYLACTIC
ANTIEPILEPTIC DRUGS (AEDs)
Efforts to reduce the incidence of PANS have included
prophylactic treatment with AEDs including benzo-
diazepines,24,45 phenobarbital,10,13,17,21,24,27,32 potassium
bromide,23,24,26 and levetiracetam.34,39,41,45–48,60 None of
these has unequivocally been demonstrated to reduce the
incidence of PANS in dogs with cPSS; however, without
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measurement of plasma drug concentrations, any conclu-
sions regarding the efficacy of these AEDs is tentative.
7.1 | Levetiracetam
There are conflicting reports regarding the possible pro-
tective effect of prophylactic treatment with levetiracetam
against development of PANS. In one retrospective
study,34 none of 42 dogs that had received preoperative
levetiracetam, 20 mg/kg every 8 h (q8) for at least 24 h,
experienced PAS, whereas four (4.8%) of 84 dogs that had
not received levetiracetam developed PAS. This observa-
tion, however, was not supported by four subsequent
larger retrospective studies.39,41,46,48 In one retrospective
study,41 6 (11.1%) of 54 dogs that had received prophylac-
tic levetiracetam (20 mg/kg q8 for ≥24 h preoperatively
and for ≥5 days postoperatively) developed PANS,
whereas 22 (11.1%) of 199 dogs that had not received
levetiracetam experienced PANS. Investigators also found
a similar incidence of PAS among dogs that had or had
not received levetiracetam (5.6% and 4.5%, respectively).41
In another large retrospective study,46 the incidence of
PAS was not significantly different among dogs that did
(11.2%) or did not (6.7%) receive levetiracetam at
≥15 mg/kg q8 for ≥24 h preoperatively or a 60 mg/kg
intravenous loading dose perioperatively, both followed
by ≥15 mg/kg q8 postoperatively. However, the same
levetiracetam protocol was not followed in all cases in
that study.46 A limitation of all published studies describ-
ing prophylactic treatment with levetiracetam is their ret-
rospective nature and lack of randomization and
standardization of treatment.34,39,41,46–48 Some studies pro-
vide no information regarding preoperative or postoperative
dose or duration of levetiracetam.39,48 In the study by Fryer
and colleagues,34 some dogs did not receive any postopera-
tive levetiracetam, with the authors placing emphasis on
pretreatment. According to a pharmacokinetic study,61 fail-
ure to continue levetiracetam postoperatively, and at the
appropriate dosage (20 mg/kg q8), would be expected to
result in plasma drug concentrations decreasing below the
recommended therapeutic range (5-45 μg/ml) after approxi-
mately 12 h. In another study,39 some dogs prescribed
levetiracetam received concurrent phenobarbital and/or
potassium bromide, a practice that has been shown to alter
the pharmacokinetics of levetiracetam significantly.62,63
Wallace and colleagues60 described the administration of
levetiracetam for a median (range) of 23 (1-29) days preop-
eratively and four (2-4) weeks postoperatively in six dogs
that underwent cEHPSS attenuation with a polyacrylic
acid-silicone device, none of which experienced PANS, but
that study did not include a control group.
7.2 | Phenobarbital
Prophylactic treatment with phenobarbital has not been
demonstrated to reduce the incidence of PANS but one
retrospective study suggested that it may reduce its severity.13
In that study,13 prophylactic phenobarbital (5-10 mg/kg
before induction followed by 3-5 mg/kg q12 for 3 weeks post-
operatively) did not significantly decrease the incidence of
PANS (6.5%) compared with a control population (15.5%).
However, no dog that received phenobarbital experienced
generalized PAS.13 Inadequacy of presurgical loading was
suggested as a reason for failure to prevent PANS in that
study completely, although serum phenobarbital concentra-
tion at the time of PANS occurrence was within therapeutic
range in the one dog in which it was measured.34 In a retro-
spective study involving 106 dogs,21 PANS were observed in
9.4% dogs despite most having received perioperative pheno-
barbital (5-10 mg/kg) and for 2 weeks postoperatively
(2-5 mg/kg q12).
7.3 | Potassium bromide
Few studies report prophylactic treatment with potas-
sium bromide and a protective effect has not been identi-
fied.23,26 In a retrospective study involving 28 dogs with
cIHPSS,26 one dog that had received a 24-h preoperative
loading regimen of potassium bromide (100 mg/kg q6)
experienced PAS. However, no information is provided
regarding the overall number of dogs that received pro-
phylactic potassium bromide.26 In another retrospective
study involving 168 dogs with cEHPSS,23 four (8.3%) of
48 dogs that had received preoperative treatment with
potassium bromide (44-100 mg/kg q24 for at least two
weeks preoperatively) developed PAS compared with
four (3.3%) of 120 dogs that did not receive potassium
bromide. No information is provided regarding whether
treatment was continued postoperatively in affected dogs.
8 | TREATMENT OF
POSTATTENUATION NEUROLOGIC
SIGNS
The idiopathic nature of PANS precludes accurate
treatment of a specific cause.12,41 Treatment is there-
fore centered around providing supportive care mea-
sures and controlling neurologic signs using AEDs,
including benzodiazepines,1,2,4,8,13,16–18,21,23,32,45,47 barbi-
turates,1,2,4,10–13,16–18,21,23,26,32,38,43,47 propofol,12,13,16,21,32,38,47
levetiracetam,41,43,45,47 alfaxalone,47 potassium bro-
mide,12,13,22,38,41,43,47 α-2 agonists,38,47 and benzodiazepine
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antagonists.47 There are no prospective randomized studies
evaluating efficacy of one or more AEDs/treatment proto-
cols. In a retrospective study involving 93 dogs affected by
PAS,47 no drug was associated with improved short-term
survival in the multivariable analysis. A limitation of cur-
rent literature is that treatment is nonrandomized and
based on clinician preference. Because multiple AEDs
are often administered concurrently and more aggres-
sive treatments are likely to have been administered to
more severely affected cases, interpretation of results is diffi-
cult.12,13,16,32,38,41,47 No consensus exists regarding best practice
treatment of PAS or more subtle PANS. Generalized PAS in
particular are often refractory to treatment and thus very chal-
lenging to control.1,2,4,6,7,9–13,16,18–21,23,26,31,32,34,35,38,39,41,44 In
some cases, mild neurologic signs resolve without treatment,
whereas other cases progress to refractory seizures, highlight-
ing that very close monitoring is required.2,11,13,16,17,20,23,41
Treatment of PANS with benzodiazepines is controversial.64
As discussed previously, one older study51 suggested a decline
in systemic concentrations of endogenous benzodiazepines
after shunt attenuation could precipitate PAS. This would sug-
gest that prophylactic treatment with benzodiazepines may be
efficacious in the prevention or treatment of PANS. However,
in the majority of studies in which an assessment of the
response to treatment of PANS with benzodiazepines is possi-
ble, they failed to control neurologic signs, particularly in cases
of generalized PAS.2,4,8,13,16–18,23,32,34,41 There are several
reports of treatment of PAS with propofol CRI,12,16,32,38,41,47
typically resulting in rapid control of even refractory seizures.
Anecdotally, it has been suggested that use of propofol for
management of PAS may be associated with elimina-
tion of external manifestations of seizure activity but
may not arrest the brain activity causing the seizures.
To our knowledge, this has not been investigated in
dogs. Prior to the first reports of using propofol for con-
trol of PAS,12,16 barbiturates including pentobarbital
and thiopental were administered in cases refractory to
benzodiazepines.2,13 There are several reports of treat-
ment of PANS and specifically PAS with phenobarbital,
with mixed but mostly positive results.2,10,11,13,17,18,26,41
While levetiracetam is relatively frequently described
as a prophylactic AED in recent literature,34,39,41,45–
48,60 there are few reports describing its efficacy in the
treatment of PANS.41,43,45,47 In one retrospective
study,41 9 dogs with PANS received treatment with
levetiracetam, including 5 dogs with PAS. However, in
8 of those 9 dogs, other AEDs including phenobarbital
and propofol were administered concurrently with
levetiracetam, and in 1 case, PAS were described as
refractory to levetiracetam.41 Treatment of PAS with
levetiracetam was also not significantly associated with
short-term survival in a more recent study.47
9 | SURVIVAL/PROGNOSIS
The 30-day survival rate in studies of ≥4 dogs
affected by PANS overall is 0%-100% (median,
50.0%)2,4,6,11,13,20,21,23,24,28,34,39,41,43,44,47,48,50 and for PAS
specifically (n ≥ 4 dogs) is 0%-75.0% (median, 37.5%)
(Appendix S3 in File S1).2,4,6,13,20,23,24,34,39,41,47,48,50 Such
variation in survival rates is likely related to varying
numbers of dogs within reports and those with general-
ized versus focal PAS or more subtle PANS, different
levels of experience in treating PANS and the extent to
which they are treated, and possibly the managing clini-
cian's perception of prognosis. Dogs that experience
PANS other than PAS and those that experience focal
PAS only (in comparison to generalized PAS) have a bet-
ter outlook for survival.11,13,15,18,20,23,26,28,34,39,41,44,47 In a
large retrospective study,41 all dogs with PANS other than
seizures survived to discharge compared with the
7 (58.3%) of 12 dogs that experienced PAS. In another ret-
rospective study,20 dogs that experienced seizures or
coma did not respond to treatment, whereas all those
with more mild PANS survived. However, knowing that
mild PANS are associated with a better prognosis has
limited prognostic value as it is impossible to predict
whether more subtle neurologic signs will progress to sei-
zures.2,11,13,16,17,20,23 Among 76 dogs with generalized
PAS in one study,47 13 (17.1%) were recorded as having
experienced focal PAS that later progressed to general-
ized PAS. Generalized PAS may be more refractory to
treatment, more distressing for the owner to observe,
associated with a greater financial cost and the percep-
tion of a poorer prognosis for recovery, all of which may
influence the decision to euthanize.13,47 In a retrospective
study involving 7 dogs with PAS,23 all dogs with focal
PAS only survived to discharge, whereas none of those
with generalized PAS survived. In another retrospective
study involving 93 dogs with PAS,47 only 32.3% dogs sur-
vived to 30 days; however, the majority experienced gen-
eralized PAS, which were significantly associated with
mortality. In that study,47 21.1% of dogs with generalized
PAS survived to 30 days in comparison to 82.4% of dogs
with focal PAS only (P = .0003). Dogs with PAS that
had a history of preoperative seizures had significantly
(P = .004) increased odds of survival to 30 days compared
with those that did not have preoperative seizures.47 This
corroborates findings of an earlier retrospective study39
in which dogs with a history of preoperative seizures that
subsequently experienced PAS had a sevenfold increased
probability of survival (to discharge) compared with
those without a history of preoperative seizures . It is pos-
sible that PAS experienced by both subsets of dogs may
have a different etiopathogenesis or some dogs with
8 MULLINS ET AL.
preoperative seizures (related to HE) may have continua-
tion of these seizures postoperatively.39,46,47 There are no
large-scale studies investigating neurologic outcomes of
dogs affected by PANS that survive to 30 days but several
reports document reoccurrence of seizure activity in the
long term (>30 days).2,4,10,12,13,16,38 Without follow-up
assessment of shunt closure, it is possible that return of
neurologic signs or seizures could be related to the
reoccurrence or persistence of HE because of residual or
acquired shunting. If affected dogs survive to discharge, sur-
vival for several years is possible.3,32,38 On the basis of the
overall small number of published reports, and specifically
those describing long-term outcomes, and inconsistent
follow-up times within reports, it is difficult to provide
meaningful prognostic information regarding survival time
and neurologic outcomes to owners of affected
dogs.2,4,10,12,13,16,32,38 The majority of neurologic signs
manifested as part of PANS appear to resolve,2,4,10,13,16,38
however, exact timing of resolution of signs is difficult to
determine due to inconsistent follow up and lack of stan-
dardization of follow-up times. There are also no published
studies investigating the long-term quality of life of dogs
affected by PANS.
10 | CONCLUSION
The development of PANS is a potentially devastating
complication after cPSS attenuation in dogs. Overall,
PANS (including PAS) affect 1.6%-27.3% of dogs. Pos-
tattenuation seizures are described predominantly after
attenuation of cEHPSS, with a reported incidence of 0%-
18.2%; however, this may reflect the greater frequency of
cEHPSS in dogs compared with cIHPSS. The etiology of
PANS remains elusive; however, a number of risk factors
have been identified, including increasing age and pres-
ence of HE immediately preoperatively. A history of pre-
operative seizures is associated with improved survival
for dogs that develop PAS. Certain breeds may also be
predisposed to PANS. There is increasing evidence to sug-
gest that prophylactic treatment with levetiracetam does
not prevent PANS. Treatment of PANS is supportive and
centered around administration of AEDs as the idio-
pathic nature of PANS precludes specific treatment. Gen-
eralized PAS can be particularly refractory to treatment
and the prognosis for dogs affected by such is generally
poor. Dogs with less severe PANS are more likely to sur-
vive but progression to more severe signs has been
reported. Overall, if affected dogs survive to discharge,
survival for several years is possible, and the majority of
neurologic signs manifested as part of PANS appear to
resolve.
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